Company ProfilePremium

Medlab Clinical Limited

Company Profile Analysis

Ticker: MDC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Medlab Clinical Limited - Company showcase

Year Founded & Workforce

2012

78 Employees

Medlab Clinical Limited logo

Medlab Clinical Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Medlab Clinical Limited Overview

Medlab Clinical was an Australian clinical-stage biotechnology company. It began as a research-driven, practitioner-only nutraceutical business. From about 2018 to 2022 it repositioned around NanoCelle®, its patented sub-micron delivery platform for oro-buccal, intranasal and transdermal administration. The lead asset was NanaBis™, a 1:1 synthetic CBD and dronabinol buccal spray targeting cancer-induced bone pain as an opioid-sparing therapy. NanaBis was available under Australia's Special Access Scheme and the UK named-patient programme, and was preparing for a multinational Phase III trial. The company sold its Australian nutraceutical business to PharmaCare in November 2021 to fund that pivot. It then attempted a Nasdaq dual listing, which collapsed in January 2023 into a funding crisis. Trading was suspended, most staff were retrenched, the core IP was sold to the founder for a contingent royalty, and the company sought a reverse takeover into strategic minerals. That deal was not completed, and the entity was delisted in February 2025. Today it is a non-operating shell with no disclosed business.


Company's own description (latest disclosures)

The FY2024 Annual Report (lodged 4 Nov 2024) no longer describes an operating business. It states that ASX suspended trading on 27 February 2023. Hall Chadwick was engaged as external consultants for an informal workout. The company retrenched most of its workforce and operated in a care-and-maintenance capacity while the directors devised a corporate restructure. Note 3 (Operating segments) records that, after the nutraceuticals business was discontinued in FY2022, the group had a single segment. The note also says the group "does not have any products/services it derives revenue from" (FY2024 AR, Note 3).

The last full description of an operating business is in the October 2022 F-1. There the company called itself an Australian biotechnology company that develops fixed-dose combinations of the NanoCelle® delivery platform with active pharmaceutical ingredients (APIs). It stated an aim to disrupt the delivery-platform market for pain and mental-health pharmaceuticals, and a revenue strategy built on licensing its IP and assets to large established companies.

Business model and revenue model (historical)

Model elementFY2015–FY2021 (pre-pivot)FY2022–FY2023 (pharma pivot)FY2024 onward (shell)
Primary activityPractitioner-only nutraceuticals (34 formulations by 2019) plus clinical researchNanoCelle®-based drug development (NanaBis, NanoCBD, MDC2000), real-world evidence under SAS / named-patient accessCare and maintenance; search for a reverse-takeover asset
Revenue typeProduct sales through pharmacy wholesale (API/Priceline, TerryWhite Chemmart, Symbion), mostly practitioner channelProduct sales of NanaBis/NanoCBD under SAS; royalties and licence fees (PharmaCare, Cultech, YesHealth, American Nutritional Corp)Residual pharmaceutical sales of A$11,894 in FY2024; contingent 20% royalty to "Entitled Shareholders" from Dr Hall (paid directly to shareholders, not to the company)
Product / service / licensing mixMostly productMixed product plus licensing; licensing was the stated strategic priority—
Non-operating fundingEquity placements; R&D Tax Incentive refundsR&D Tax Incentive (A$2.87M recognised FY2023); grantsDebt forgiveness (A$0.09M); Hall Chadwick fees accrued against future equity

Value-chain position

Medlab was an asset-light IP owner and developer. The F-1 states it had no in-house manufacturing and relied on third parties. Those included Renaissance Lakewood LLC (US CDMO, FDA/DEA experienced), Natural Factors (Canada, TGA-approved), Extractas (formerly Tasmanian Alkaloids), and Purisys LLC (Georgia, US) for biosynthetic CBD and dronabinol with FDA Drug Master Files. It did own an OGTR-registered laboratory in Sydney, where NanoCelle was developed, and handled formulation, clinical design, regulatory filings and real-world-evidence collection itself.

Customer types and end-markets

Prescribers and patients: Australian doctors prescribing under the TGA Special Access Scheme; UK prescribers under the MHRA named-patient programme. More than 1,000 Australian patients were under clinical management on NanaBis by 2022 (Stockhead, Q3 FY2022 update), and over 1,200 by July 2022 (Q4 FY2022 4C).

Pharmacy and practitioner channel (until Nov 2021): integrative-medicine practitioners and community pharmacy banner groups.

Licensees and distributors: PharmaCare (Australia/NZ), Cultech (UK), YesHealth (Malaysia/Vietnam/Singapore), American Nutritional Corporation (US, NuScripts private label), Mega Lifesciences (heads of agreement for NanaBis global distribution).

Therapeutic end-markets: cancer-induced bone pain and neuropathic pain, occupational stress and mild chronic pain, major depressive disorder, gut health, diabetes and obesity (exploratory), allergies, and nasal nucleic-acid vaccines (pre-clinical).

Independent characterisation

Medlab was a sub-scale, founder-led micro-cap biotech. It tried to bridge a cash-generating consumer-health business and a capital-hungry regulated-drug pipeline, and ultimately could do neither. The PharmaCare divestment (A$1.6M cash, per the F-1) removed most recurring revenue just as Phase III and FDA costs were set to rise. The company then depended on a single external financing event, the Nasdaq IPO, which failed amid a hostile biotech funding market in late 2022. The platform thesis (NanoCelle sub-micron buccal delivery) had real IP: patents granted in the US, Europe, Australia and other jurisdictions to 2036. But it never produced a registered (approved) prescription medicine, a pivotal efficacy readout, or a licensing deal with a large pharmaceutical company. The entity's endgame, a related-party sale of the IP to the founder for a contingent royalty followed by a failed minerals RTO, is typical of ASX shell outcomes for failed micro-cap biotechs.

Strategy

Stated strategy (pharma era, F-1, October 2022)

The F-1 set out five strategic pillars, paraphrased here:

  1. advance the investigational drug candidates toward US and other approvals;

  2. use accelerated access routes, including compassionate-use programmes in the US, UK and Australia;

  3. develop further clinical products for unmet needs;

  4. maintain a strong IP estate in key markets to 2036;

  5. expand global availability.

The revenue strategy was explicitly licence-led: partner with large established companies rather than build commercial infrastructure.

Initiatives in the last 24 months of reported activity (Nov 2022 – Feb 2025)

DateInitiativeOutcome
Jun 2022 – Jan 2023Nasdaq dual listing (MDLB) to raise about US$7M net (Edison)Abandoned 20 Jan 2023
Nov 2022UK named-patient launch of NanaBis/NanaDolImport permission obtained; scale not disclosed
2022–2023NanaBis Phase III (about 360 patients; US/UK/Australia) and US INDNever commenced
Feb–Mar 2023Informal workout with Hall Chadwick; 78% headcount reduction; lease exitCompleted; company placed in care and maintenance
May 202320% reduction in executive hoursImplemented
Aug–Nov 2023Search for recapitalisation, restructure or asset sale; proposed licence of NanoCelle to an unrelated party plus a capital raisingLicence not completed; replaced by the related-party sale
12 Jan 2024Sale of IP and US subsidiaries to Dr Sean Hall for a 20% royalty to Entitled Shareholders over 4 yearsCompleted
2,024Reverse takeover of a strategic-minerals business (net-zero commodities); A$5M raise; quotation expected 3–4 months after a dealNo binding agreement announced; deadline missed
28 Feb 2025—Delisted

ESG and sustainability commitments: None disclosed. The FY2024 AR states the group was not subject to significant environmental regulation.

Medium-term financial targets and guidance: None issued.

Products & Services

All products below were owned through Medlab IP Pty Ltd or licensed by the group before 12 January 2024. The listed entity no longer owns them. The rights now sit with Dr Sean Hall's interests, subject to the 20% shareholder royalty.

Platform technology

ProductDescriptionKey specificationsTarget customerLaunch / statusPricing model
NanoCelle®Proprietary sub-micron (nanoparticle) delivery platformParticles of 1–100 nm; routes include oro-buccal/sublingual spray, intranasal spray, dermal and transdermal, topical, oral gel capsules and liquids, adsorption from solid carriers. Designed to bypass gastrointestinal and first-pass hepatic absorption so lower doses can be used. Over 350,000 doses administered via compassionate use, trials and sales (F-1, Oct 2022). Patented in Australia, Canada, EU/EPC states, Hong Kong, NZ, US and UK, with Singapore pending; protection to 2036Pharma licensees, CDMOs, consumer-health partnersDeveloped in Medlab's OGTR-registered lab; US patent granted Oct 2021Licensing and royalty; technology-transfer licences to manufacturers

Prescription and investigational pharmaceuticals

ProductDescription and indicationStage (last disclosed)Regulatory pathwayKey details
NanaBis™ (UK: "NanaDol")1:1 (50:50) synthetic CBD and dronabinol (synthetic THC) buccal spray via NanoCelle, for cancer-induced bone pain as an opioid-sparing analgesic; potential extension to neuropathic painPhase II at an Australian hospital met primary and secondary endpoints (F-1). Phase III planned with about 360 participants in the US, Australia and UK, using a randomised-withdrawal monotherapy design. Edison expected enrolment in Q4 CY2023, which never happened. Real-world dataset of 1,172+ patientsARTG-registered (F-1); TGA Special Access Scheme; UK named-patient programme (MHRA import permission 25 Nov 2022); US FDA-led programme with API Drug Master File via PurisysLead asset. Switched to 100% synthetic APIs during COVID on FDA guidance
NanoCBD™CBD-only NanoCelle buccal spray for occupational stress and mild chronic painPK/PD studies in healthy volunteers planned for mid-2023 (F-1)TGA-led over-the-counter registered-medicine pathway; MHRA named-patient approval Apr 2022Shares DMF, CMC and US manufacturing with NanaBis
NanaBidial™Cannabinoid formulation for cancer pain (earlier-generation programme)Development status not updated after c.2018ODC export licence covered itAppears to have been superseded by NanaBis
MDC2000Single molecule encapsulated in NanoCelle for major depressive disorderReturned to pre-clinical after a 2020 study closed early due to COVID; clinical restart expected early 2023 (not executed)Candidate for an FDA 505(b)(2) NDA—
NanoCelle® Nucleic Acid ("Nasal RNA")Nasal delivery of siRNA and RNA vaccinesPre-clinical. NanoCelle-insulin nasal adherence studies met endpoints; siRNA encapsulation was the next stepTGA-focused; government-funded collaborationIP jointly owned one-third each with UNSW and Macquarie University
NanoCelle® atorvastatinBuccal statin for hypercholesterolaemiaPhase 0 planned (c.2018)Reformulation of an existing moleculeNo later disclosure found
NanoCelle® insulinBuccal/nasal insulin for Type II diabetesPhase 0 planned (c.2018); nasal adherence work completed by 2022Reformulation of an existing molecule—

Consumer health / nutraceuticals (divested or licensed)

ProductDescriptionStatusLicensee / channel
NanoCelle® D3Vitamin D3 spray for immunity and bone health; ARTG-listedSold OTC through PharmaCare in Australia and as a food supplement in NZ (Medsafe)PharmaCare (Aus/NZ); American Nutritional Corp (US, NuScripts)
NanoCelle® B12Vitamin B12 spray to lower homocysteine and support the nervous system; ARTG-listedAs aboveAs above
NRGBiotic™Patented probiotic for patients with major depressive disorder; manufactured by Cultech Ltd (UK)Three-year UK trade deal, with European/US optionalityCultech Ltd (UK exclusive, US non-exclusive)
Practitioner-only nutraceutical range34 formulations by 2019, many patent-protected; microbiome-focused research. 29 products transferred to PharmaCareAustralian rights sold to PharmaCare effective 1 Nov 2021; rights outside Australia retained (F-1/A)PharmaCare (Australia); YesHealth (12 products, Malaysia/Vietnam exclusive, Singapore non-exclusive)

Product-level pricing was not publicly disclosed for any product. YesHealth supply was on a cost-plus basis plus royalties on net sales (Stockhead).

Financial Narrative

Primary source: the FY2024 Annual Report's five-year summary (FY2020–FY2024) and its audited FY2023/FY2024 statements. FY2020–FY2022 line items beyond revenue and loss come from the Kalkine aggregator, which draws on company filings, and are labelled. FY2025 figures were not publicly disclosed.

Income statement

Notes. (a) The company's 5-year summary and Stockopedia's revenue series diverge for FY2021–FY2022. The difference most likely reflects the restatement of nutraceutical revenue into discontinued operations; both are shown. (b) The Q4 FY2022 Appendix 4C cites "full-year cash operating revenues" of A$6.2M, a cash-receipts measure that includes divestment-related inflows and is not comparable to accounting revenue. (c) Derived FY2023 EBIT = loss before tax (-6.433) + finance costs (0.033) - interest revenue (0.052). FY2023 EBITDA adds back D&A of 0.711. FY2023 gross profit = revenue (0.892) - raw materials (0.090). (d) Kalkine shows FY2022 income before tax of -8.388, against a company after-tax loss of -7.229; the gap is probably discontinued-operations results. The company figure is used. (e) EPS is restated for the 150:1 consolidation.

Margins and growth

Revenue CAGR FY2020–FY2024 (company series): -74.6% a year (derived). Stockopedia reports -71.52% on its own series. Margins use the company revenue series; FY2020–FY2022 gross margin uses the Kalkine gross profit, which may be on a different revenue basis, so treat it as indicative.

Balance sheet

Sources: FY2024 AR statements of financial position, changes in equity (FY2022 = 1 July 2022 opening balances), and the cash-flow note. FY2024 payables include A$920,443 accrued to Hall Chadwick, payable only in shares if the company re-lists. Hall Chadwick has said under a non-binding term sheet that it will not enforce this if no re-listing occurs. Interim data: cash was A$9.75M at 30 Sep 2021 and A$11.22M at 31 Dec 2021 (Kalkine), A$8.6M at 31 Mar 2022 (Stockhead) and A$5.2M at 30 Jun 2022 (Q4 FY2022 4C). Unused Australian tax losses at 30 Jun 2024 were A$31.39M, not recognised; FY2023 also had US$5.67M in the US and £0.22M in the UK.

Ratios

Interest coverage and net debt/EBITDA are not meaningful (negative EBITDA, negligible interest). FY2024 ROE is not meaningful because average equity turned negative. Stockopedia shows trailing ROE of -993.58% and operating margin of -14,833.74%, on unstated periods.

Commentary

Revenue. Revenue peaked at about A$4.4M in FY2021 on the company basis, at the height of the pharmacy nutraceutical rollout that began with the 2019 API/Priceline and TerryWhite agreements. It then fell away in three steps: the November 2021 sale of the Australian nutraceutical business to PharmaCare, the switch to small SAS and named-patient pharmaceutical volumes (A$0.89M in FY2023), and the cessation of operations (A$11,894 in FY2024). At no point did Medlab have a revenue base that covered its cost base.

Losses and the R&D Tax Incentive. Attributable losses narrowed from A$13.4M (FY2020) to A$7.2M (FY2022). That reflected cost control and the shift to an asset-light model, not revenue growth. In FY2023 the R&D Tax Incentive (A$2.87M recognised, A$3.69M received in cash) was the single largest source of funds, larger than product revenue by a factor of about three. That dependence made the business fragile: once R&D spending stopped, the refund disappeared too.

Balance sheet erosion. Equity fell from A$7.75M (1 Jul 2022) to A$1.28M (30 Jun 2023) and then to a deficiency of A$0.85M (30 Jun 2024). FY2024 operating cash outflow was only A$0.17M, but only because the final A$2.74M R&D refund arrived. Cumulative contributed capital of A$66.8M against accumulated losses of A$67.7M means shareholders' entire paid-in capital has been consumed.

Inflection points. Two decisions shaped the outcome. First, the FY2022 divestment of nutraceuticals removed the only recurring revenue. Second, the January 2023 withdrawal of the US$7M net Nasdaq offering (Edison) left a cash runway that, in Edison's estimate, extended only into March 2023. Suspension followed within five weeks.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segments Reported by Period

PeriodSegments reportedContents

Up to FY2021

Two: Pharmaceuticals and Nutraceuticals (inferred from the FY2024 AR statement that the Nutraceuticals business was discontinued in FY2022)

Pharmaceuticals: NanaBis, NanoCBD, pipeline. Nutraceuticals: 29–34 practitioner-only formulations including NanoCelle D3 and B12

FY2022 restatement

Nutraceuticals reclassified as discontinued after the 1 Nov 2021 PharmaCare sale

Pharmaceuticals became the continuing segment

FY2023–FY2024

One segment

FY2024 AR Note 3 states there are no products or services generating revenue

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024

Pharmaceuticals revenue (AUD Mn, company AR)

—0.8920.012

Nutraceuticals revenue (AUD Mn, discontinued)

—00

Pharmaceuticals % of total revenue

100100100

Pharmaceuticals revenue YoY growth (%)

——-98.7

Group Entities

EntityCountryFY2023 ownership (%)FY2024 ownership (%)Status

Medlab Clinical Limited

Australia

Parent

Parent

Delisted 28 Feb 2025; legal status after delisting not disclosed

Medlab Pty Ltd

Australia

100100

Only remaining subsidiary at 30 Jun 2024

Medlab IP Pty Ltd

Australia

1000

Sold to Dr Sean Hall, 12 Jan 2024

Medlab Clinical US Inc

USA

1000

Sold to Dr Sean Hall, 12 Jan 2024

Medlab Research Pty Ltd

Australia

1000

Deregistered FY2024

Medlab Nutraceuticals Inc

USA

600

Deregistered FY2024 (source of the non-controlling interest)

Medlab Research Ltd

UK

1000

Deregistered Jan 2024

MDC Europe Ltd

Malta

1000

Deregistered FY2024

Income Statement and Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024

Revenue, company 5-yr summary (AUD Mn)

2.8484.3993.8040.8920.012

Revenue, aggregator continuing-ops basis (AUD Mn, Stockopedia)

2.920.761.330.940.01

Other income incl. R&D tax incentive (AUD Mn)

———3.4620.127

Gross profit (AUD Mn; FY20–22 Kalkine; FY23 derived)

0.041.460.950.802—

EBIT (AUD Mn; FY20–22 Kalkine; FY23–24 derived)

-13.291-12.346-8.344-6.452-2.133

EBITDA (AUD Mn; FY20–22 Kalkine; FY23–24 derived)

-12.330-11.472-7.492-5.741-2.133

Depreciation and amortisation (AUD Mn)

0.960.870.850.7110

Pre-tax income (AUD Mn)

-13.488-12.403-7.229-6.433-2.131

Net income after tax, total (AUD Mn)

-13.488-12.403-7.229-6.433-2.131

Net income attributable to owners (AUD Mn)

-13.399-12.324-7.162-6.778-2.131

Basic EPS (A$ cents, consolidation-adjusted)

-891-627-314-297-93

Diluted EPS (A$ cents)

-891-627-314-297-93

Dividends per share (A$ cents)

00000

Margin Analysis (%)

MetricFY2020FY2021FY2022FY2023FY2024

Gross margin (%)

1332590—

EBITDA margin (%)

-433-261-197-644-17,933

Operating (EBIT) margin (%)

-467-281-219-723-17,924

Net margin, attributable (%)

-470-280-188-760-17,914

Revenue YoY growth (%, company series)

—54.5-13.5-76.5-98.7

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024

Cash and equivalents (AUD Mn)

5.1910.2260.110

Trade and other receivables (AUD Mn)

—2.8680.001

of which R&D tax incentive receivable (AUD Mn)

—2.7350

Total current assets (AUD Mn)

—3.0940.111

Total assets (AUD Mn)

—3.1440.111

Total current liabilities (AUD Mn)

—1.8510.962

Total liabilities (AUD Mn)

—1.8640.962

Short-term borrowings (AUD Mn)

000

Long-term borrowings (AUD Mn)

000

Lease liabilities (AUD Mn)

1.12300

Net debt incl. leases (AUD Mn; negative = net cash)

-4.068-0.226-0.110

Total equity (AUD Mn)

7.7491.280-0.851

Issued capital (AUD Mn)

66.81166.81166.811

Accumulated losses (AUD Mn)

-59.529-65.648-67.662

Goodwill and intangibles (AUD Mn)

—00

Working capital (AUD Mn)

—1.244-0.851

NTA per share (A$ cents)

—56.06-37.26

Cash Flow

MetricFY2020FY2021FY2022FY2023FY2024

Operating cash flow (AUD Mn)

———-5.470-0.166

of which R&D tax incentive and grant receipts (AUD Mn)

———3.6922.735

Capex (AUD Mn)

———0.0160

Free cash flow (AUD Mn, derived)

———-5.486-0.166

Divestment proceeds, deferred consideration (AUD Mn)

———0.4710

Lease principal repaid (AUD Mn)

———0.4820

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Equity raised (AUD Mn)

———00

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024

ROE (%, attributable loss / average equity)

—-150—

ROA (%, loss / closing assets)

—-216-1,913

Current ratio (x)

—1.670.12

Debt / equity (x, incl. leases)

0.1400

Asset turnover (x, revenue / closing assets)

—0.280.11

Revenue by Region

RegionFY2022FY2023FY2024

Total group revenue (AUD Mn)

3.8040.8920.012

Region Assets & Liabilities and Revenue by Region

IndicatorFY2023

Foreign-currency liabilities, USD (AUD Mn)

0.766

Foreign-currency liabilities, GBP (AUD Mn)

0.002

Realised FX gain (AUD Mn)

0.568

Per-Share Data and Share Price

MetricFY2020FY2021FY2022FY2023FY2024

FY-end share price, pre-consolidation (A$ cents)

15155——

FY-end share price, consolidation-adjusted (A$, derived ×149.85)

22.4822.487.496.606.60

Shares on issue, post-consolidation basis (M)

——2.2842.2842.284

Return metric

Return metricValue

1-year (to Oct 2026)

n/m: no trading since 27 Feb 2023; delisted

3-year

n/m

5-year (Oct 2021 – last trade, approx.)

Strongly negative. The price fell from about 15c pre-consolidation (about A$22.48 adjusted) at June 2021 to A$6.60, roughly -71% (derived), before accounting for loss of liquidity on delisting

Relative performance (Stockopedia, date unstated)

Underperformed the ASX All Ordinaries by 67.48% over one year and by 50.82% over six months

Valuation Multiples

MultipleMedlab (FY2023 basis)Medlab (FY2024 basis)

P/E

n/m (loss)

n/m (loss)

EV/EBITDA

n/m (negative EBITDA)

n/m

EV/Sales (x)

16.6

n/m

P/B (x)

11.8

n/m (negative equity)

Source Details

SourceDateView

Edison Investment Research (issuer-sponsored)

Dec 2022

Nasdaq listing on track for Q1 CY2023; NanaBis the key catalyst

Edison Investment Research

Jan 2023

NanaBis probability of success cut from 45% to 35%; cash runway into March 2023; equity raise likely dilutive

Market Index

2024–2025

Not covered by a major broker

Consensus estimates

—

None. A Stockopedia "2025E revenue A$6.8M" entry is stale and unreliable, given the FY2024 actual of A$0.012M

Capital Markets

ItemDetail

Dividend history

Never paid (FY2020–FY2024 AR)

Dividend policy

No intention to pay in the foreseeable future (F-1)

Buyback authorisations

None (FY2024 AR, Note 11)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No borrowings. Trade payables of A$962,261 due within one year, of which A$920,443 is the Hall Chadwick accrual, settleable only in shares on re-listing

Capital history

A$66.81M contributed capital, including the A$24M placement (Jan 2018) and an A$15M placement (date not confirmed)

Analyst Conclusions

Management guidance

None. The last forward-looking statement (FY2024 AR, 4 Nov 2024) was that the directors were in advanced negotiations to acquire a strategic-minerals business, funded by a A$5M raise and taking about 3–4 months to quotation. No binding agreement was announced before the 27 Feb 2025 deadline, and the entity was delisted.

Consensus expectations

None. There is no broker coverage, no quotation and no published estimates.

Bull case (for residual stakeholders)

  1. Royalty optionality. Entitled Shareholders hold a 20% royalty to about January 2028 on NanoCelle IP that is patented to 2036 across major markets. Any licence or commercial launch by Dr Hall's vehicle would flow partly to them, at no cost to the shell.

  2. Shell plus tax losses. A$31.39M of Australian tax losses, no debt and a contingent-only adviser liability make a small unlisted shell potentially attractive for a back-door listing or a merger, if the ownership tests can be met.

  3. Directors able to source deals. A board with resources-finance and structured-finance networks (Hudson, Walker, Tan) is positioned to find a transaction; a renewed minerals RTO with a fresh admission to the ASX remains theoretically possible.

Bear case

  1. Equity has no economic value. Net liabilities of A$0.85M, cash of A$0.11M and no business at 30 June 2024; delisting removes liquidity and disclosure obligations.

  2. Royalty value is uncertain and hard to enforce. It is owed by a related private party, there is no public reporting of receipts, NanaBis Phase III never began, and US scheduling constraints persist.

  3. Execution track record. Repeated failures (Nasdaq IPO, NanoCelle licence, minerals RTO) and lapses in governance compliance argue against a successful recapitalisation.

Catalysts and monitorables (next 12 months)

  • Any ASIC filings showing a change of status (deregistration, administration or liquidation) for Medlab Clinical Limited.

  • Any announcement of a new ASX admission or reverse takeover involving the entity.

  • Royalty statements or payments to Entitled Shareholders from Dr Hall or his associated entity.

  • Public commercialisation activity on NanaBis or NanoCelle by the private successor: licences, FDA IND or Phase III starts, UK named-patient expansion.

  • Release of FY2025 or FY2026 financial statements, if any are lodged with ASIC.

  • Whether Hall Chadwick converts or waives its A$920k accrued fees.

Analyst verdict

Medlab Clinical Limited is no longer an investable listed company. It is a delisted, non-operating Australian shell. Its last audited balance sheet (30 June 2024) showed A$111k of assets, A$962k of liabilities and A$67.7M of accumulated losses, which exceed every dollar shareholders contributed over the company's life. FY2025 accounts have not been publicly disclosed. Since removal from the ASX on 28 February 2025, no further corporate disclosure has been found.

The failure has three identifiable causes. First, strategic sequencing. Management divested the only revenue-generating business, practitioner nutraceuticals, for A$1.6M in November 2021, before securing the capital needed for a US Phase III programme in cannabinoid analgesia. Second, single-point financing risk. Funding the next stage depended almost entirely on a roughly US$7M Nasdaq IPO, launched into the weakest micro-cap biotech market in a decade; when it was shelved in January 2023, the cash runway ended within weeks. Third, structural difficulty in the asset. NanaBis competed for regulatory and commercial attention with an already approved THC:CBD oromucosal spray, and faced Schedule I complexity in the US. Its evidence base was largely real-world data from Special Access Scheme patients rather than controlled trials.

The workout delivered what remained of the scientific value through a related-party sale of the IP to the founder. The consideration was a four-year, 20% royalty paid directly to shareholders on the register at settlement. Any residual economic value for former MDC holders now sits mostly in that royalty, not in the shell. The shell's potential value lies in its tax losses and shareholder register, both contingent on a transaction that has not materialised.

Verdict: No investment case for the entity. For former shareholders, the only practical asset is a contingent royalty claim. They should verify their Entitled Shareholder status and seek a copy of the 12 January 2024 sale agreement. Monitor ASIC records for status changes.


Principal sources consulted

  • Medlab Clinical Limited, Appendix 4E and Annual Report for the year ended 30 June 2024 (ASX, 4 Nov 2024): financial statements, notes 1–24, Remuneration Report, shareholder information, corporate directory.

  • Medlab Clinical Ltd., SEC Form F-1 (13 Oct 2022) and Forms F-1/A and DRS (2022), CIK 1940322.

  • ASX announcement indexes (InvestSMART, Market Index, TipRanks): suspension, long-term suspension notices, removal from the Official List (28 Feb 2025), results of meetings (14 Feb 2025).

  • Medlab ASX releases: Appendix 4C Q4 FY2022 (29 Jul 2022); EPO Notice of Intention to Grant; ASX aware letter.

  • Edison Investment Research notes on Medlab (2021–2023).

  • GlobeNewswire (4 Nov 2021) on the US NanoCelle patent grant.

  • Trade press: Pharmacy Daily (2018, 2019, 2021), Retail Pharmacy Magazine (2021), Biotech Dispatch, NutraIngredients-Asia (2019), Stockhead (2021–2022), Smallcaps, Kalkine (2022), Drug Target Review, The Greenfields newsletter (2023).

  • Aggregators, used for secondary data only and labelled: Kalkine, Stockopedia, IBISWorld, Pearler.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenureBackgroundShareholding

Matthew Hudson

Non-Executive Chairman

Director from 6 Mar 2023; Chair from 25 Mar 2024

BCom. Former Credit Suisse and Arthur Andersen adviser; co-founder and MD of Hudson Koch Energy (43 oil and gas wells in Kansas and Oklahoma); founder and MD of United Minerals (historic Potosi Mine, Chihuahua, Mexico)

Nil

Edmond Tan

Non-Executive Director

From 25 Mar 2024

BCom. 10+ years in private wealth, family office and structured finance; director of Regenerate Pty Ltd (rare-earth magnet recycling, Houston); Australian representative of Obsidian Global Partners LLC, a structured financier for ASX-listed companies

Nil

Tim Walker

Non-Executive Director

From 25 Mar 2024

BCom. Resources corporate finance; M&A in Canada and Australia; past exploration directorships covering lithium, rare earths/niobium, iron ore and base metals

Nil

Kerem Kaya

CFO, Company Secretary and COO (consultant since 1 Sep 2023)

Employee from 13 May 2021; terminated 31 Aug 2023; re-engaged at A$4,750 a month

BCom, CPA; previously at Novartis

Nil (options expired 24 Jun 2024)

Board of Directors

NameRoleTenure endBackground

Dr Sean Hall

Founder; MD and CEO; Executive Chairman

Resigned 25 Mar 2024

MD, MBA (Clinical Pharmaceutical Marketing). Over 20 years in Australian healthcare and food industries; built the BioCeuticals practitioner brand; Harvard executive and continuing medical education. Born 1970 (Kalkine)

Michael Hall

Non-Executive Chairman

Resigned 6 Mar 2023

Former Head Office Controller at Grace Brothers; chairman of Quantum Health Group

Drew Townsend

Non-Executive Director

Resigned 26 Feb 2023

Former senior partner at Hall Chadwick

Cheryl Maley

Non-Executive Director

18 Oct 2021 – 26 Feb 2023

Pharmaceutical executive with US (Chicago) and Asia (Philippines) postings; oncology regulatory experience

Laurence McAllister

Non-Executive Director

Resigned 31 Aug 2022

Not detailed

Mohit Gupta

Non-Executive Director

8 Aug 2022 – 13 Mar 2023

Not detailed

Michael Carter

Non-Executive Director

13 Mar 2023 – 25 Mar 2024

BCom (UWA), GradDipAppFin. Stockbroker since 1999; associate director of CPS Capital Group; NED of European Lithium Ltd

Jeremy Henson

Director of Medical Research

19 Jul 2022 – 2 Mar 2023 (redundant)

—

Luis Vitetta

Executive (research)

Resigned 20 Jul 2022

—

Ian Curtinsmith

Executive

Redundant 2 Mar 2023

—

David Rutolo

Executive

Redundant 30 Jun 2023

—

Alan Dworkin

CFO (c.2019)

Before 2021

Cited in 2019 investor briefings

Directors' Remuneration

PersonYearSalary / feesBonusSuperannuationLong-service leaveTerminationTotal

Sean Hall

FY2024

58,84606,47380,434281,972427,725

Sean Hall

FY2023

415,192043,5957,0790465,866

Kerem Kaya

FY2024

35,81305,529086,731128,073

Kerem Kaya

FY2023

250,447026,28500276,732

Matthew Hudson

FY2024

65,000000065,000

Matthew Hudson

FY2023

20,000000020,000

Michael Carter

FY2024

49,725000049,725

Michael Hall

FY2023

115,38506,86500122,250

Cheryl Maley

FY2023

44,200000044,200

Mohit Gupta

FY2023

39,826000039,826

Ian Curtinsmith

FY2023

181,57030,00018,161027,596257,327

Jeremy Henson

FY2023

196,071019,128038,501253,700

David Rutolo

FY2023

178,244013,63600191,880

Total KMP

FY2024

209,384012,00280,434368,703670,523

Total KMP

FY2023

1,540,61730,000129,2327,07966,0971,773,025

Major Shareholders

RankHolderShares%
1

Mr Sean Michael Hall

389,04117.04
2

Farjoy Pty Ltd

205,6639.01
3

HSBC Custody Nominees (Australia) Ltd

88,2293.86
4

UBS Nominees Pty Ltd

85,3163.74
5

FIT Investments Pty Ltd (Hallab Investment A/C)

75,5633.31
6

Realm Group Pty Ltd

54,7052.40
7

Citicorp Nominees Pty Ltd

49,7982.18
8

Mr Drew Anthony Townsend (Townsend Family A/C)

37,0381.62
9

Richard Albarran (Albarran Family No 2 A/C)

37,0381.62
10

United Trolley Collections P/L

32,9701.44

Competitive Landscape

Competitors by Segment

SegmentCompetitorRelevance

Cannabinoid prescription medicines

Jazz Pharmaceuticals (Nasdaq: JAZZ; acquired GW Pharmaceuticals 2021)

Owner of Epidiolex and Sativex (nabiximols, a THC:CBD oromucosal spray), the closest approved analogue to NanaBis

Cannabinoid prescription medicines

Zelira Therapeutics (ASX: ZLD)

Cannabinoid drug developer (pain and insomnia)

Cannabinoid prescription medicines

Incannex Healthcare (Nasdaq: IXHL; formerly ASX)

Cannabinoid combination drugs; redomiciled to the US

Cannabinoid prescription medicines

Emyria (ASX: EMD)

Real-world-evidence-led cannabinoid and MDMA programmes

Cannabinoid OTC / CBD

Bod Science (ASX: BDA; formerly Bod Australia)

Low-dose CBD (MediCabilis/CBD-based OTC)

Medicinal cannabis supply and SAS

Cann Group (ASX: CAN)

Former partner; supplies SAS and Authorised Prescriber markets

Medicinal cannabis distribution

Vitura Health (ASX: VIT; formerly Cannatrek/Doctors on Demand group)

Digital clinics and distribution in the Australian SAS market

Novel delivery / enhanced bioavailability

Avecho Biotechnology (ASX: AVE)

TPM delivery platform with a CBD programme

Buccal / transmucosal delivery

Aquestive Therapeutics (Nasdaq: AQST)

PharmFilm buccal and sublingual film platform

Buccal opioid / pain delivery

Collegium Pharmaceutical (Nasdaq: COLL; acquired BioDelivery Sciences 2022)

BEMA buccal delivery in pain

Practitioner nutraceuticals (historical)

BioCeuticals (Blackmores Group, now part of Kirin)

Practitioner channel leader that Sean Hall had built

Practitioner nutraceuticals (historical)

PharmaCare, Metagenics

Practitioner/pharmacy supplement competitors (PharmaCare later the acquirer)

Peer Comparison FY2024

MetricMedlab Clinical (FY2024)Medlab Clinical (FY2023)

Revenue

A$0.012M

A$0.892M

Revenue growth

-98.7%-76.5%

Net margin

n/m

-760%

R&D intensity

0%

137% (reported line only)

Recent Developments

The 18 months before today (Apr 2025 – Oct 2026) contain no disclosed developments: the entity was delisted on 28 Feb 2025, and no later public announcements were found. The register therefore covers the last 30 months of disclosure (Aug 2022 – Feb 2025).*

Company Snapshot

78

Employees

2012

Founded

Alexandria, Australia

Headquarters

SWOT Analysis

Strengths

  • Clean liability structure: no borrowings, no lease liabilities and no contingent liabilities at 30 June 2024 (FY2024 AR, Notes 14 and 17).
  • Large tax-loss shelf: A$31.39M of unrecognised Australian tax losses at 30 June 2024 (FY2024 AR, Note 7). These are potentially valuable to a reverse-takeover acquirer, subject to continuity-of-ownership and similar-business tests.
  • Contingent royalty for shareholders: 20% royalty on the sold IP for four years from 12 January 2024, payable to Entitled Shareholders (FY2024 AR, Note 18).
  • Hall Chadwick fees deferred: A$920,443 is payable only in shares on re-listing and will not be enforced otherwise (FY2024 AR, Note 10), so it is effectively not a cash liability.
  • Unmodified audit opinion: FY2024 accounts received an unmodified opinion with an emphasis of matter on going concern (Appendix 4E, item 10).
  • Historical platform validation: NanoCelle patents granted in the US (No. 11160753), Europe, Australia, Canada, Hong Kong and NZ to 2036 (F-1; GlobeNewswire, Nov 2021). This supports the value of the royalty stream.

Weaknesses

  • Net liabilities: A$850,883 deficiency at 30 June 2024; NTA of -37.26 cents per share (Appendix 4E).
  • No revenue-generating business: FY2024 AR Note 3 says there are no products or services from which revenue is derived.
  • Minimal cash: A$110,093 at 30 June 2024 (Note 8).
  • Delisted: removed 28 Feb 2025, so shareholders have no liquidity.
  • Governance lapses: the FY2023 report was lodged about 10 months late (24 Apr 2024), and no AGM was held between Sept 2022 and Feb 2025 (FY2024 AR; TipRanks).
  • Accumulated losses of A$67.66M exceed contributed capital of A$66.81M (FY2024 AR).

Opportunities

  • Reverse takeover: the directors were negotiating a strategic-minerals deal with a A$5M raise and 3–4 months to quotation (FY2024 AR, Note 1).
  • Royalty monetisation: if Dr Hall's private vehicle commercialises NanaBis or licenses NanoCelle, Entitled Shareholders receive 20% until about January 2028.
  • Tax-loss utilisation: A$31.39M of losses could shelter future profits of a merged business, subject to the tax tests.
  • Unlisted transactions: an off-market sale of the shell is possible; the 4,952-holder register is a modest asset.
  • Regulatory tailwinds for opioid-sparing analgesia: these benefit the royalty-bearing IP (Edison framing).
  • Directors' network: directors with resources-finance backgrounds (Hudson, Walker) and access to structured finance (Tan via Obsidian) improve the odds of sourcing a deal (FY2024 AR director bios).

Threats

  • Deadline missed: no binding RTO agreement was disclosed before the 27 Feb 2025 deadline, and delisting followed (InvestSMART; TipRanks).
  • Shell deregistration or insolvency: with net liabilities and no listed-capital access, going concern now depends wholly on unlisted recapitalisation (FY2024 AR, Note 1).
  • Royalty enforcement risk: the royalty is payable by a private, related-party counterparty, and no receipts have been publicly reported (FY2024 AR, Note 18).
  • Tax-loss forfeiture: a change of ownership on any RTO may fail the continuity-of-ownership test.
  • Information vacuum: without ASX continuous disclosure, holders have no assured information flow.
  • Low IP value realisation: NanaBis Phase III never started, and the US DEA/CSA constraints remain (F-1), so royalty revenue may be nil.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
5 Aug / 1 Sep 2022150:1 share consolidationPre-Nasdaq capital restructure
8 Aug 2022Mohit Gupta appointed NEDBoard refresh
31 Aug 2022Laurence McAllister resignsBoard turnover
30 Sep 2022AGM; remuneration report passed (93.76%)Last AGM until 2025
13 Oct 2022F-1 filed with the SECUS IPO formally launched
31 Oct 202212M director options (2020 grant) expire unexercisedIncentive overhang removed
1 Nov 2022Notification of cessation of securitiesOptions lapse
25 Nov 2022MHRA import permission for NanaBisUK commercial access
1 Dec 2022First IP royalty tranche from PharmaCareSmall non-dilutive inflow
8 Dec 2022SEC comments clearedIPO appeared on track for Q1 CY2023
Mid-Jan 2023NanaBis real-world-evidence update (1,172 patients; 77 continued past 12 months; 400+ discontinued, per newsletter commentary)Data quality questioned by commentators
20 Jan 2023Nasdaq IPO shelvedFunding failure
26 Feb 2023Townsend and Maley resignBoard exodus
27 Feb 2023ASX suspensionTrading ceases permanently
2 Mar 2023Redundancies; about 78% of staff laid off; Hall Chadwick engagedOperations wound down
6 Mar 2023Chair Michael Hall resigns; Hudson joinsLeadership change
13 Mar 2023Carter joins; Gupta resignsBoard reconstituted with corporate-finance profiles
22 May 2023Executive hours cut 20%Cash preservation
30 Jun 2023FY2023 closes: A$0.23M cash, A$2.74M R&D refund receivableLiquidity bridge
3 Aug 2023Recapitalisation campaign updateStrategic review
31 Aug 2023CFO employment ends; re-engaged as consultantCost reduction
12 Sep 2023Further recapitalisation update—
9 Nov 2023Proposed NanoCelle licence to an unrelated partyRestructure path 1
22 Nov 2023Restructure transaction update—
12 Jan 2024IP and US subsidiary sold to Sean HallCore asset leaves the group
Jan 2024UK subsidiary deregisteredFootprint collapse
29 Feb 2024Share registry changed to AutomicAdministrative
25 Mar 2024Sean Hall and Carter resign; Tan and Walker appointed; Hudson becomes ChairFounder exit; pivot to resources
28 Mar 2024Auditor ESV resigns; MNSA confirmedAudit continuity
24 Apr 2024FY2023 Annual Report lodged (late)Compliance catch-up; company pledged improved governance
10 Jul 2024ASX long-term suspension deadline set (27 Feb 2025)Delisting clock started
18 Oct 2024Listed among ASX Long Term Suspended Entities—
4 Nov 2024FY2024 Annual Report: net liabilities A$0.85M; minerals RTO under negotiationGoing-concern dependence on RTO
4 Dec 2024Board composition changes–
22 Jan 2025Again listed as a long-term suspended entity—
3 Feb 2025Quarterly Appendix 4C (Dec 2024 quarter)–
14 Feb 2025Results of the 2023 and 2024 AGMsOverdue governance compliance
28 Feb 2025Removal from the ASX Official ListEnd of listed life

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue, company 5-yr summary fell from AUD 2.8 Mn in FY2020 to AUD 0 Mn in FY2024.
Medlab Clinical Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2020FY2021FY2022FY2023FY2024
Revenue, company 5-yr summary2.84.43.80.90
Revenue, aggregator continuing-ops basis2.90.81.30.90
Gross profit01.510.8—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.